Lumida
/ILMN
⌘K
Illumina Inc

Illumina Inc

ILMN
$186.65USD↓-1.89%-3.60 today

MARKET CAP

28.2B

P/E (TTM)

37.1x

FWD P/E

33.0x

DAY RANGE

$184 – $190

52W RANGE

$88
$197

AI Summary

Stalk
Buy NowMedium

After a corrective pullback within a broader uptrend, ILMN remains in Stage 2 advancing structure above rising EMAs. Price has pulled back into the 9/20 EMA support zone and held, offering a favorable entry for continuation. While an active Bullish Exhaustion pattern signals short-term momentum weakening, the corrective move into EMAs qualifies as a healthy reset, supporting medium-term bullish continuation under the High Momentum strategy.

  • ↑Clinical consumables revenue grew 20% YoY to $726M, driving 65% of total.
  • ↑Gross margin expanded to 68.2% in Q1 2026, reflecting efficient cost management.
  • ↓Stock trades ~30% above cash flow valuation, raising valuation concerns.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Illumina, Inc. (NASDAQ: ILMN) is a leading player in the genomics space, specializing in DNA sequencing and array-based solutions designed to support clinical diagnostics and research. The company provides innovative technologies that are critical for applications in oncology, reproductive health, and broader genetic analysis, positioning itself as a pivotal player in the rapidly evolving landscape of personalized medicine and diagnostics. As a dominant market leader, Illumina is integral to the ongoing genomic revolution, characterized by increasing adoption of next-generation sequencing (NGS) technology.

Bull says

  • ↑Clinical consumables revenue grew 20% YoY to $726M, driving 65% of total.
  • ↑Gross margin expanded to 68.2% in Q1 2026, reflecting efficient cost management.
  • ↑Positive earnings revisions signal analyst optimism on future EPS growth.
  • ↑Authorized $1.5B in buybacks, spending $242M in Q1, highlighting robust cash returns.
  • ↑Somalogic acquisition boosts multiomics pipeline, targeting proteomics revenue synergies.
  • ↑High profitability and liquidity support sustained operational flexibility.

Bear says

  • ↓Stock trades ~30% above cash flow valuation, raising valuation concerns.
  • ↓Research segment growth weakens amid funding headwinds outside clinical markets.
  • ↓High share price volatility heightens investment risk for conservative holders.
  • ↓Low institutional ownership indicates limited confidence in long-term strategy.
  • ↓Somalogic integration may strain operations and delay expected synergies.
  • ↓Negative earnings yield and balance-sheet metrics signal potential return shortfalls.

Investment themes with ILMN

Robotics↑ +0.45%

Robotics and automation technology companies

IPGP · ZBRA · 6954.T

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-01-2026neutral

Transcript signals

Bull points

  • we do think there is a lot of value in our Spatial solution. Overall, I do think, as you're saying, it's something that raises all the votes right now.
  • I’m pretty sure we have a winner when we come here out later in the year with our spatial solution.
  • we saw very, very strong placements in 25 years. I think more than 1,000 placements we have announced on that.

Bear points

  • Given you have seen 20% of clinical growth for two consecutive quarters now, would it be fair to assume continued momentum throughout the year?
  • We do have inflationary pressure from things like the component cost and the freight, etc.
  • we haven't built much of that into our guide right now. So I consider that more on an upside.
Read full transcript analysis ›